Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial
Autor: | Hiroshi Koike, Hiroshi Urakawa, Kunihiro Ikuta, Kan Ito, Yuichi Ando, Tomohisa Sakai, Yoshihiro Nishida, Ryo Emoto, Shigeyuki Matsui, Shunsuke Hamada |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Cancer Research desmoid medicine.medical_treatment Kaplan-Meier Estimate Corrections Gastroenterology 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Child Univariate analysis General Medicine Middle Aged Prognosis Vinblastine Fibromatosis Aggressive Treatment Outcome Oncology biweekly Child Preschool 030220 oncology & carcinogenesis Female Original Article medicine.drug Adult medicine.medical_specialty Adolescent Drug Administration Schedule methotrexate Young Adult 03 medical and health sciences Clinical Research Internal medicine vinblastine medicine Humans Adverse effect Aged Neoplasm Staging Proportional Hazards Models Chemotherapy business.industry clinical benefit rate Original Articles Discontinuation Clinical trial Regimen 030104 developmental biology Methotrexate business Follow-Up Studies |
Zdroj: | Cancer Science Cancer Sci |
ISSN: | 1349-7006 1347-9032 |
Popis: | Low‐dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid‐type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m2) + VBL (6 mg/m2). Efficacy, progression‐free survival (PFS), and correlating factors were analyzed. Adverse events (AEs) were recorded. In total, 38 patients received low‐dose MTX + VBL therapy, and its efficacy was assessed in 37 of them. Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo. Longer duration of therapy was significantly associated with the response of PR (P = .007) by univariate analysis. There was no clear association between various clinicopathological factors, including tumor size, location, catenin beta‐1 (CTNNB1) mutation status with effect. Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients. Biweekly administration of MTX + VBL chemotherapy was well tolerated compared with weekly administration, and its efficacy was anticipated in DF patents, although the time needed to achieve a response may be relatively long. The treatment interval should be determined taking into account both the condition of the tumor and the patient's preference. Biweekly administration of MTX + VBL chemotherapy for desmoid patients was well tolerated compared with weekly administration, and its efficacy was similar. The time needed to achieve a response may be relatively long with a biweekly regimen. |
Databáze: | OpenAIRE |
Externí odkaz: |